Jürgen Floege

Q: What Schools Are Affiliated With Jürgen Floege

Jürgen Floege is affiliated with the following schools: Hannover Medical School, RWTH Aachen University, University of Washington

Jürgen Floege's AcademicInfluence.com Rankings

Jürgen Floege

Medical

#1361

World Rank

#1689

Historical Rank

Nephrology

World Rank

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Jürgen Floege Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jürgen Floege's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis (2012) (1147)
The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. (2003) (933)
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study (2003) (911)
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (2012) (885)
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. (2012) (795)
Renal injury from angiotensin II-mediated hypertension. (1992) (555)
Renal fibrosis: novel insights into mechanisms and therapeutic targets (2010) (521)
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. (2011) (511)
Recruitment of podocytes from glomerular parietal epithelial cells. (2009) (436)
Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. (1992) (430)
Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens (2014) (430)
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population (2010) (417)
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. (2021) (414)
Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor (1992) (359)
Cellular events in the evolution of experimental diabetic nephropathy. (1995) (334)
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial (2017) (317)
Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. (2006) (312)
Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis (2012) (302)
A new look at platelet-derived growth factor in renal disease. (2008) (293)
Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. (1996) (280)
Increased synthesis of extracellular matrix in mesangial proliferative nephritis. (1991) (276)
Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. (2007) (266)
Genetic loci influencing kidney function and chronic kidney disease (2010) (266)
Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. (1993) (260)
Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. (2012) (259)
Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. (2004) (259)
Nanoparticle-based test measures overall propensity for calcification in serum. (2012) (249)
Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. (1999) (241)
Decoding myofibroblast origins in human kidney fibrosis (2020) (236)
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. (2005) (229)
Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. (2009) (223)
Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. (2011) (213)
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial (2017) (213)
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. (2015) (212)
The activated mesangial cell: a glomerular "myofibroblast"? (1992) (206)
Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. (1992) (203)
Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. (2009) (200)
Vascular calcification in chronic kidney disease: an update. (2016) (197)
IgA nephropathy: recent developments. (2000) (196)
Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. (2011) (191)
Vascular calcification in patients with end-stage renal disease. (2004) (187)
Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration (2013) (185)
Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. (1994) (180)
Pro-fibrogenic potential of PDGF-D in liver fibrosis. (2007) (180)
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019) (179)
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. (2015) (178)
Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. (1993) (171)
Fetuin-A protects against atherosclerotic calcification in CKD. (2009) (169)
Ultrastructural analysis of vascular calcifications in uremia. (2010) (165)
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. (2007) (161)
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. (2015) (161)
Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. (1993) (159)
A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients (2014) (159)
Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. (1995) (157)
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. (2021) (149)
Cardiovascular Disease in Chronic Kidney Disease (2021) (147)
Primary glomerulonephritides (2016) (146)
Detection of endotoxin-like interleukin-1-inducing activity during in vitro dialysis. (1988) (145)
l-Carnosine, a Substrate of Carnosinase-1, Influences Glucose Metabolism (2007) (142)
Rat glomerular mesangial cells synthesize basic fibroblast growth factor. Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. (1992) (142)
Treatment targets in renal fibrosis. (2007) (141)
Origin of regenerating tubular cells after acute kidney injury (2014) (140)
Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. (2017) (139)
European consensus statement on the terminology used in the management of lupus glomerulonephritis (2009) (137)
The Montreal Cognitive Assessment (MoCA) - A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients (2014) (136)
Development and validation of a predictive mortality risk score from a European hemodialysis cohort (2015) (135)
Use of phosphate-binding agents is associated with a lower risk of mortality. (2013) (135)
Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. (2001) (133)
Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. (2015) (131)
Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. (2014) (131)
Calcification and Cardiovascular Health: New Insights Into an Old Phenomenon (2006) (131)
β2-microglobulin associated amyloidosis: A vanishing complication of long-term hemodialysis? (1997) (131)
Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. (1997) (130)
Beta-2-microglobulin-associated amyloidosis. (1996) (130)
Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis. (2008) (129)
Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. (2003) (126)
Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. (1997) (124)
Role of platelet-derived growth factor in glomerular disease. (1993) (123)
The German Chronic Kidney Disease (GCKD) study: design and methods. (2012) (123)
Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. (2015) (122)
Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. (1991) (120)
Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry (2016) (120)
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients (2015) (120)
High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. (2015) (119)
Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. (2006) (118)
WNT–β-catenin signalling — a versatile player in kidney injury and repair (2020) (115)
PDGF in organ fibrosis. (2017) (114)
Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019) (113)
Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial (2014) (112)
Calcification Propensity and Survival among Renal Transplant Recipients. (2016) (110)
Visceral glomerular epithelial cells can proliferate in vivo and synthesize platelet-derived growth factor B-chain. (1993) (110)
Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system. (2000) (109)
Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury in vivo. Expression of antiadhesive proteins and cytoskeletal changes. (1992) (109)
Albumin is recycled from the primary urine by tubular transcytosis. (2013) (108)
Complement C5 mediates experimental tubulointerstitial fibrosis. (2007) (108)
Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries. (2017) (105)
PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. (2008) (104)
Sodium thiosulfate in the treatment of calcific uremic arteriolopathy (2009) (104)
Slower Progress of Aortic Valve Calcification With Vitamin K Supplementation: Results From a Prospective Interventional Proof-of-Concept Study. (2017) (103)
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. (2019) (103)
A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. (2003) (102)
Quantitative Micro-Computed Tomography Imaging of Vascular Dysfunction in Progressive Kidney Diseases. (2016) (101)
Treatment of Renal Fibrosis-Turning Challenges into Opportunities. (2017) (100)
The mucosa–kidney axis in IgA nephropathy (2016) (100)
Adynamic bone disease—bone and beyond (2008) (100)
β2-Microglobulin–derived amyloidosis: An update (2001) (99)
Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. (1997) (98)
Recurrent IgA nephropathy after renal transplantation. (2004) (98)
Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification (2009) (97)
The regenerative potential of parietal epithelial cells in adult mice. (2014) (97)
Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury (2008) (97)
High cardiovascular event rates occur within the first weeks of starting hemodialysis (2015) (97)
Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? (2009) (97)
Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. (2007) (95)
The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. (2015) (95)
Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. (2012) (95)
The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? (2011) (93)
Warfarin Induces Cardiovascular Damage in Mice (2013) (93)
Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. (2006) (93)
The renal (myo-)fibroblast: a heterogeneous group of cells. (2012) (91)
Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. (2014) (91)
Chronic kidney disease growth factors in renal fibrosis (2011) (90)
Current therapy for IgA nephropathy. (2011) (90)
GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway (2016) (89)
Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients. (2016) (89)
Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin-dependent diabetes mellitus. (2001) (86)
Rodent models of nephropathy associated with type II diabetes. (1999) (86)
The PDGF family in renal fibrosis (2012) (86)
Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. (2003) (86)
Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function. (2010) (85)
Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. (1995) (84)
Role of contact system activation in hemodialyzer-induced thrombogenicity. (2001) (84)
Multiple roles for platelet-derived growth factor in renal disease. (1995) (84)
Clearance and synthesis rates of beta 2-microglobulin in patients undergoing hemodialysis and in normal subjects. (1991) (83)
High-flux synthetic versus cellulosic membranes for beta 2-microglobulin removal during hemodialysis, hemodiafiltration and hemofiltration. (1989) (82)
Treatment of IgA nephropathy and Henoch–Schönlein nephritis (2013) (82)
Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors α and β in activated rat hepatic stellate cells (HSC) (2005) (82)
Notch‐3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury (2012) (82)
SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids (2021) (82)
Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. (2008) (81)
Y-box Protein-1 Is the Crucial Mediator of Antifibrotic Interferon-γ Effects* (2006) (81)
Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. (1994) (81)
PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. (2003) (81)
Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. (2010) (81)
COSMOS: the dialysis scenario of CKD-MBD in Europe. (2013) (80)
Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease. (2011) (79)
PDGF and the progression of renal disease. (2014) (79)
Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. (2013) (79)
Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. (2014) (79)
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. (2019) (78)
Vascular access calcification predicts mortality in hemodialysis patients. (2008) (77)
Pathways to recovery and loss of nephrons in anti-Thy-1 nephritis. (2003) (77)
Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. (2014) (76)
Renal Allograft Fibrosis: Biology and Therapeutic Targets (2015) (76)
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. (2015) (75)
Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. (2014) (74)
Expression of a novel PDGF isoform, PDGF-C, in normal and diseased rat kidney. (2002) (70)
Mesangial cells in the pathogenesis of progressive glomerular disease in animal models (1992) (70)
Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. (2006) (70)
Keratins are novel markers of renal epithelial cell injury. (2016) (70)
Cardiac Remodeling in Chronic Kidney Disease (2020) (69)
In vivo identification of the mitogen-activated protein kinase cascade as a central pathogenic pathway in experimental mesangioproliferative glomerulonephritis. (2002) (69)
Recurrent glomerulonephritis following renal transplantation: an update. (2003) (68)
Role of T cells and dendritic cells in glomerular immunopathology (2007) (68)
Podocyte Damage Resulting in Podocyturia: A Potential Diagnostic Marker to Assess Glomerular Disease Activity (2007) (67)
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. (2013) (65)
Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. (2009) (64)
Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. (2011) (62)
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. (2020) (61)
Association of SGK1 Gene Polymorphisms with Type 2 Diabetes (2008) (60)
Novel Insights into Uremic Vascular Calcification: Role of Matrix Gla Protein and Alpha-2-Heremans Schmid Glycoprotein/Fetuin (2002) (60)
Platelet-derived growth factor: a potentially important cytokine in glomerular disease. (1992) (60)
PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. (2007) (59)
Common histological patterns in glomerular epithelial cells in secondary focal segmental glomerulosclerosis. (2015) (59)
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in HemodialysisCLINICAL PERSPECTIVE (2015) (59)
Imaging of dialysis-related amyloid (AB-amyloid) deposits with 131I-beta 2-microglobulin. (1990) (58)
Subtotal ablation of parietal epithelial cells induces crescent formation. (2012) (58)
Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss. (2018) (58)
beta2-microglobulin-derived amyloidosis: an update. (2001) (57)
Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. (2013) (57)
Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. (2017) (56)
YB-1 Is an Early and Central Mediator of Bacterial and Sterile Inflammation In Vivo (2013) (56)
Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. (1997) (56)
Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC). (2005) (56)
Primary Cultures of Glomerular Parietal Epithelial Cells or Podocytes with Proven Origin (2012) (55)
Influence of body mass index on the association of weight changes with mortality in hemodialysis patients. (2013) (55)
Exposure to Uremic Serum Induces a Procalcific Phenotype in Human Mesenchymal Stem Cells (2011) (55)
Hemodialysis-related induction of beta-2-microglobulin and interleukin-1 synthesis and release by mononuclear phagocytes. (1989) (54)
Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases. (2015) (54)
Deep Learning-Based Segmentation and Quantification in Experimental Kidney Histopathology. (2020) (54)
Effects of rhGH and rhIGF-1 on renal growth and morphology. (1993) (53)
Clinical predictors of individual cognitive fluctuations in patients undergoing hemodialysis. (2014) (53)
Y-box protein-1 is the crucial mediator of antifibrotic interferon-gamma effects. (2006) (53)
Modulation of experimental mesangial proliferative nephritis by interferon-gamma. (1995) (53)
Electrical forces determine glomerular permeability. (2010) (53)
Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. (2013) (53)
Phosphate binders in chronic kidney disease: a systematic review of recent data (2016) (53)
The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. (2002) (53)
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. (2012) (53)
Elastin imaging enables noninvasive staging and treatment monitoring of kidney fibrosis (2019) (53)
Big science and big data in nephrology. (2019) (52)
Expression of A20 in the vessel wall of rat-kidney allografts correlates with protection from transplant arteriosclerosis (2003) (52)
Expression of PDGF alpha-receptor in renal arteriosclerosis and rejecting renal transplants. (1998) (52)
Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. (1992) (51)
Differential regulation of chemokine CCL5 expression in monocytes/macrophages and renal cells by Y-box protein-1. (2009) (51)
Glomerular cells in vitro versus the glomerulus in vivo. (1994) (51)
Macrophage Migration Inhibitory Factor Limits Renal Inflammation and Fibrosis by Counteracting Tubular Cell Cycle Arrest. (2017) (50)
Heat shock protein 60 is released in immune-mediated glomerulonephritis and aggravates disease: in vivo evidence for an immunologic danger signal. (2005) (49)
CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. (2008) (49)
Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. (2018) (49)
Immune complex formation in IgA nephropathy: a case of the 'right' antibodies in the 'wrong' place at the 'wrong' time? (2009) (49)
Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D. (2011) (49)
Progression of Diabetic Nephropathy (1999) (48)
Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. (2020) (48)
Role of interferon-γ gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study (2006) (48)
Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells. (2006) (47)
Improving hand hygiene compliance rates in the haemodialysis setting: more than just more hand rubs. (2012) (47)
Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? (2016) (47)
Recurrent IgA nephropathy after kidney transplantation: not a benign condition. (1998) (47)
Localization of PDGF α-receptor in the developing and mature human kidney (1997) (47)
Development and validation of cardiovascular risk scores for haemodialysis patients. (2016) (46)
Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. (1998) (46)
Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis (2014) (45)
Investigations of Glucocorticoid Action in GN. (2017) (45)
When man turns to stone: extraosseous calcification in uremic patients. (2004) (45)
Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis? (1997) (44)
Extracellular YB-1 Blockade in Experimental Nephritis Upregulates Notch-3 Receptor Expression and Signaling (2011) (44)
The quest for a model of type II diabetes with nephropathy: the Goto Kakizaki rat. (2004) (44)
Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy. (2016) (44)
Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis: A Double-Blind, Randomized, Placebo-Controlled Trial. (2016) (44)
Steroid-related osteonecrosis--an update. (2011) (44)
Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. (2010) (43)
PDGF-C mediates glomerular capillary repair. (2010) (43)
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy (2020) (43)
Localization of fibroblast growth factor-2 (basic FGF) and FGF receptor-1 in adult human kidney. (1999) (43)
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide (2016) (43)
Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. (2013) (43)
Activation of the acute phase response and complement C3 in patients with IgA nephropathy. (2000) (43)
Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. (2002) (42)
Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation? (1994) (42)
IL-6 Trans-Signaling Drives Murine Crescentic GN. (2016) (42)
Biocompatibility of Peritoneal Dialysis Fluids: Long-term Exposure of Nonuremic Rats (2004) (42)
Risk Factors for Cardiovascular Calcifications in Non-Diabetic Caucasian Haemodialysis Patients (2009) (42)
Y-Box Binding Protein-1 Mediates Profibrotic Effects of Calcineurin Inhibitors in the Kidney (2011) (42)
Diffusion‐weighted MRI does not reflect kidney fibrosis in a rat model of fibrosis (2015) (42)
Origin of parietal podocytes in atubular glomeruli mapped by lineage tracing. (2014) (42)
Urinary Exosomes: A Novel Means to Non-Invasively Assess Changes in Renal Gene and Protein Expression (2014) (41)
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. (2016) (41)
Dialysis related amyloidosis: a disease of chronic retention and inflammation? (1992) (41)
Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. (2009) (41)
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases (2021) (40)
Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse. (2005) (39)
Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions (2019) (39)
Early experience with COVID-19 in kidney transplantation (2020) (39)
New insights into the pathogenesis of IgA nephropathy (2014) (38)
Magnesium in CKD: more than a calcification inhibitor? (2014) (38)
cAMP-responsive Element Modulator α (CREMα) Contributes to Decreased Notch-1 Expression in T Cells from Patients with Active Systemic Lupus Erythematosus (SLE)* (2012) (38)
Clot Structure: A Potent Mortality Risk Factor in Patients on Hemodialysis. (2017) (38)
The Genetic Evolution of Melanoma (2016) (37)
The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. (2005) (37)
Progression of renal failure: what is the role of cytokines? (1995) (37)
Lumbar bone mineral density in very long-term renal transplant recipients: Impact of circulating sex hormones (2005) (37)
Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits. (2006) (37)
“Missing” inhibitors of calcification: general aspects and implications in renal failure (2005) (37)
The role of PDGF-D in healthy and fibrotic kidneys. (2016) (36)
Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneys. (2020) (36)
Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. (2018) (36)
Novel insights into renal fibrosis (2003) (35)
Prognostic impact of renal arterial resistance index upon renal allograft survival: the time point matters. (2012) (35)
Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients. (2008) (34)
Analysis of calcifications in patients with coral reef aorta. (2010) (34)
The vulnerable patient with chronic kidney disease. (2016) (34)
R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. (2005) (33)
Cellular and Molecular Mechanisms of Kidney Injury in 2,8-Dihydroxyadenine Nephropathy. (2020) (33)
No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. (2008) (33)
Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. (2003) (33)
Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells. (2002) (32)
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. (2022) (32)
Alterations of synovial tissue and their potential role in the deposition of beta2-microglobulin-associated amyloid. (1998) (32)
Augmentation of kidney injury by basic fibroblast growth factor or platelet-derived growth factor does not induce progressive diabetic nephropathy in the Goto Kakizaki model of non-insulin-dependent diabetes. (1999) (32)
Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? (2008) (32)
Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells. (2005) (31)
Specific imaging of dialysis-related amyloid deposits using 131I-beta-2-microglobulin. (1989) (31)
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia. (2002) (31)
Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24. (2009) (31)
Inflammation in IgA nephropathy (2017) (31)
Management of hyperphosphataemia in chronic kidney disease—challenges and solutions (2013) (30)
Therapeutic nuclear shuttling of YB-1 reduces renal damage and fibrosis. (2016) (30)
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients (2018) (30)
Calcineurin-mediated YB-1 Dephosphorylation Regulates CCL5 Expression during Monocyte Differentiation* (2014) (30)
Differential activation of memory-relevant brain regions during a dialysis cycle. (2010) (30)
Differentially Spliced Isoforms of FAT1 Are Asymmetrically Distributed within Migrating Cells* (2007) (30)
Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia. (2019) (29)
IgA nephropathy: new insights into the role of complement. (2018) (29)
Subcutaneous amyloid-tumor of beta-2-microglobulin origin in a long-term hemodialysis patient. (1989) (29)
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). (2008) (29)
Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis. (2019) (29)
Hypoglycemia following intravenous insulin plus glucose for hyperkalemia in patients with impaired renal function (2017) (29)
Recurrent IgA nephropathy in the renal allograft: not a benign condition. (2013) (29)
Henoch-Schönlein purpura complicated by cardiac involvement: case report and review of the literature. (2009) (28)
Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. (2009) (28)
Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. (2004) (28)
Current treatment of IgA nephropathy (2021) (27)
Vitamin K Antagonists: Beyond Bleeding (2014) (27)
MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application (2020) (27)
Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. (2004) (27)
Growth arrest-specific protein 1 is a novel endogenous inhibitor of glomerular cell activation and proliferation. (2013) (26)
FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients (2016) (26)
A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and antimesangioproliferative effects. (2012) (26)
Mesangial cell expression of proto-oncogene Ets-1 during progression of mesangioproliferative glomerulonephritis. (2004) (26)
Osteogenesis of Heterotopically Transplanted Mesenchymal Stromal Cells in Rat Models of Chronic Kidney Disease (2013) (26)
An Epidemiological Study of Hemodialysis Patients Based on the European Fresenius Medical Care Hemodialysis Network: Results of the ARO Study (2010) (26)
Medical options to fight mortality in end-stage renal disease: a review of the literature. (2012) (26)
Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study. (2019) (26)
A collagen-binding protein enables molecular imaging of kidney fibrosis in vivo. (2019) (25)
Key metalloproteinase-mediated pathways in the kidney (2021) (25)
Release, Upregulated Synthesis, and Mitogenicity in Mesangial Proliferative Glomerulonephritis (1992) (25)
CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC (2012) (25)
A Novel Bioimpedance Technique to Monitor Fluid Volume State During Hemodialysis Treatment (2010) (25)
Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease (2018) (25)
Urinary IgA, secretory IgA and secretory component in women with recurrent urinary tract infections. (1990) (25)
Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort (2016) (24)
Localization of PDGF alpha-receptor in the developing and mature human kidney. (1997) (24)
CHAPTER 15 – Introduction to Glomerular Disease: Clinical Presentations (2010) (24)
Phosphate binders in chronic kidney disease: an updated narrative review of recent data (2019) (24)
Clinical research for patient empowerment--a qualitative approach on the improvement of heart health promotion in chronic illness. (2008) (23)
Biological responses to PDGF-AA versus PDGF-CC in renal fibroblasts. (2013) (23)
Why Target the Gut to Treat IgA Nephropathy? (2020) (23)
Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. (2011) (23)
The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait (2005) (23)
Platelet Hyperaggregability is Highly Prevalent in Patients With Chronic Kidney Disease (2015) (23)
Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation (2018) (23)
The platelet-derived growth factor system in renal disease: an emerging role of endogenous inhibitors. (2012) (23)
Present and future therapy options in IgA-nephropathy. (2005) (23)
Association Between Dietary Patterns and Kidney Function in Patients With Chronic Kidney Disease: A Cross-Sectional Analysis of the German Chronic Kidney Disease Study. (2019) (23)
YB‐1 orchestrates onset and resolution of renal inflammation via IL10 gene regulation (2017) (22)
Immune modulating therapy for IgA nephropathy: rationale and evidence. (2008) (22)
Dysregulated mesenchymal PDGFR‐β drives kidney fibrosis (2020) (22)
No association of the -2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy. (2004) (22)
Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores) (2018) (21)
CHAPTER 22 – IgA Nephropathy and Henoch-Schönlein Nephritis (2010) (21)
Cytokines in renal inflammation (1993) (21)
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. (2022) (20)
Gas6 protein: its role in cardiovascular calcification (2016) (20)
Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. (2016) (20)
Nephrology research—the past, present and future (2015) (20)
Kidney calling lung and call back: how organs talk to each other. (2010) (20)
SGLT-2 inhibition in IgA nephropathy: the new standard-of-care? (2021) (20)
Complement C5a receptors C5L2 and C5aR in renal fibrosis. (2018) (19)
Renal side effects of anti-VEGF therapy in man: a new test system. (2007) (19)
Conversion of Goodpasture's syndrome into membranous glomerulonephritis. (2001) (19)
Calcification and the usual suspect phosphate: still guilty but there are other guys behind the scenes. (2006) (19)
Cold shock protein YB-1 is involved in hypoxia-dependent gene transcription. (2016) (19)
Hemodialysis-Related Induction of β2-Microglobulin Synthesis and Release by Mononuclear Phagocytes (1990) (19)
One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis (2017) (19)
High-fat diet-induced obesity causes an inflammatory microenvironment in the kidneys of aging Long-Evans rats (2019) (19)
Sclerostin deficiency modifies the development of CKD-MBD in mice. (2018) (19)
Recombinant versus natural human 111In-β2-microglobulin for scintigraphic detection of Aβ2m amyloid in dialysis patients (2000) (18)
Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic (2011) (18)
Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy? (2010) (18)
Is the rise in plasma beta-2-microglobulin seen during hemodialysis meaningful? (1989) (18)
Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. (2019) (18)
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial (2016) (18)
Gp130-dependent signaling in the podocyte. (2014) (17)
Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes. (1994) (17)
Role of platelet-derived growth factor-CC in capillary rarefaction in renal fibrosis. (2015) (17)
Pathogenetic and diagnostic aspects of dialysis-related amyloidosis. (1995) (17)
CD153/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury (2021) (17)
Contrast-enhanced CT imaging in patients with chronic kidney disease (2016) (17)
Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University (2018) (17)
The role of PDGF-D in mesangioproliferative glomerulonephritis. (2007) (17)
Electronic Alerts for Acute Kidney Injury. (2017) (16)
Imaging Techniques in the Diagnosis of Dialysis‐Related Amyloidosis (2001) (16)
Increased Cerebral Water Content in Hemodialysis Patients (2015) (16)
PDGF-D and renal disease: yet another one of those growth factors? (2003) (16)
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients (2016) (16)
Differential Expression of Mcp-1 and Its Receptor CCR2 in Glucose Primed Human Mesangial Cells (2002) (16)
Amyloidosis and its relationship to different dialysers. (1994) (15)
Expression of interferon-inducible Mx-proteins in patients with IgA nephropathy or Henoch-Schönlein purpura. (1999) (15)
Renal lipidosis in patients enrolled in a methadone substitution program. (2014) (15)
Magnesium Concentration in Dialysate: Is Higher Better? (2018) (15)
Comprar Comprehensive Clinical Nephrology, 4th Edition | Richard J. Johnson | 9780323058766 | Mosby (2010) (15)
Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic (2020) (15)
The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus. (2019) (15)
Underestimated complications in thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome. (2004) (14)
An efficient system for tissue-specific overexpression of transgenes in podocytes in vivo. (2005) (14)
Deep learning-based classification of kidney transplant pathology: a retrospective, multicentre, proof-of-concept study. (2021) (14)
Dialysis-related amyloidosis and high-flux membranes. (1992) (14)
Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis (2019) (14)
Combined immunosuppression in high-risk patients with IgA nephropathy? (2010) (13)
Uraemia disrupts the vascular niche in a 3D co-culture system of human mesenchymal stem cells and endothelial cells. (2012) (13)
Trends of renal diseases in Germany: review of a regional renal biopsy database from 1990 to 2013 (2019) (13)
Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all‐cause mortality† (2015) (13)
Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis. (2004) (13)
The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis. (2007) (13)
Unclear fever 7 weeks after renal transplantation in a 56-year-old patient. (2006) (13)
Therapeutic targets for prevention and regression of progressive fibrosing renal diseases. (2005) (13)
The SDF-1/CXCR4 axis is a novel driver of vascular development of the glomerulus. (2009) (13)
Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. (2019) (13)
The ERA-EDTA Database on Recurrent Glomerulonephritis following renal transplantation. (2014) (13)
Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease (2020) (13)
Epicardial adipose tissue in long-term hemodialysis patients: its association with vascular calcification and long-term development (2016) (12)
Glomerular cells in the progression of human and experimental nephropathies. (1997) (12)
Kidney protection against autoreactive CD8(+) T cells distinct from immunoprivilege and sequestration. (2001) (12)
Scintigraphic methods to detect β2‐microglobulin associated amyloidosis (Aβ2‐microglobulin amyloidosis) (2001) (12)
Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort. (2020) (12)
[Is there a correlation between C-reactive protein and calcification inhibitors with cardiovascular parameters and risk factors in hemodialysis patients?]. (2007) (11)
Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics (2008) (11)
New Aspects of Kidney Fibrosis–From Mechanisms of Injury to Modulation of Disease (2022) (11)
COVID-19 Prevalence and Mortality in Chronic Dialysis Patients. (2021) (11)
Coumarin use in dialysis patients with atrial fibrillation--more harm than benefit? (2009) (11)
The nucleic acid binding protein YB-1-controlled expression of CXCL-1 modulates kidney damage in liver fibrosis. (2019) (11)
Long‐term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients (2018) (11)
Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride (2013) (11)
Clinical features of hemodialysis patients with intimal versus medial vascular calcifications. (2009) (11)
Con: STOP immunosuppression in IgA nephropathy. (2016) (11)
Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. (2016) (11)
Primary glomerulonephritis: A review of important recent discoveries (2013) (11)
Prognostic value of cardiovascular calcifications in hemodialysis patients: a longitudinal study (2018) (11)
Mesenchymal stem cells as a therapeutic approach to glomerular diseases: benefits and risks (2011) (11)
On the specificity of assays to detect circulating immunoglobulin A-fibronectin complexes: implications for the study of serologic phenomena in patients with immunoglobulin A nephropathy. (1994) (11)
In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes. (2002) (11)
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms (2013) (10)
Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial (2021) (10)
The urinary sediment beyond light microscopical examination. (2006) (10)
Management of intraocular hypertension during hemodialysis by intravenous glucose administration. (2014) (10)
Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease. (2021) (10)
Scintigraphic methods to detect beta2-microglobulin associated amyloidosis (Abeta2-microglobulin amyloidosis). (2001) (10)
Non-invasive molecular imaging of kidney diseases (2021) (10)
A Functional Landscape of CKD Entities From Public Transcriptomic Data (2019) (10)
Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. (2021) (9)
Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery (2015) (9)
Antagonism of canonical Wnt/β-catenin signaling: taking RAS blockade to the next level? (2015) (9)
Glomerular Remodelling: Novel Therapeutic Approaches Derived from the Apparently Chaotic Growth Factor Network (2002) (9)
Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study (2020) (9)
Calcimimetics in CKD—results from recent clinical studies (2008) (9)
Vitamin K and cardiovascular complications in CKD patients. (2021) (9)
Cardiovascular disease in patients with chronic kidney disease (2020) (9)
Glomerular disease: The Oxford classification—predicting progression of IgAN (2009) (9)
Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy (2020) (9)
In search of a better understanding of IgA nephropathy-associated hematuria. (2012) (9)
The new SFB/TRR219 Research Centre. (2018) (9)
Inverse correlation between vascular endothelial growth factor back-filtration and capillary filtration pressures (2018) (8)
Cinacalcet, FGF23 and Cardiovascular Disease in Hemodialysis: The EVOLVE Trial (2015) (8)
Which membrane? Should beta-2-microglobulin decide on the choice of today's hemodialysis membrane? (1988) (8)
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia (2018) (8)
Klotho Deficiency and the Cardiomyopathy of Advanced CKD. (2015) (8)
Low adherence to CKD-specific dietary recommendations associates with impaired kidney function, dyslipidemia, and inflammation (2021) (8)
IgA nephropathy: toward more specific diagnosis (and rescue of snails). (2018) (8)
Goto-Kakizaki rat is protected from proteinuria after induction of anti-Thy1 nephritis. (2002) (8)
Bone marrow transplantation rescues Alport mice. (2006) (8)
Non-invasive evaluation of coronary heart disease in patients with chronic kidney disease using photoplethysmography (2019) (8)
An update on herpes virus infections in graft recipients. (2003) (8)
Modulation of peripheral chemoreflex by neurohumoral adaptations after kidney transplantation (2010) (8)
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics (2021) (8)
Calcification in arteriovenous fistula blood vessels may predict arteriovenous fistula failure: a 5-year follow-up study (2017) (8)
Bacterial protease for the treatment of IgA nephropathy. (2008) (7)
Littoral cell angioma of the spleen mimicking posttransplantation lymphoma in a 63-year-old renal transplant patient. (2008) (7)
Monitoring transcellular fluid shifts during episodes of intradialytic hypotension using bioimpedance spectroscopy (2019) (7)
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS (2022) (7)
CHAPTER 81 – Bone and Mineral Metabolism in Chronic Kidney Disease (2010) (7)
Cytokines and Growth Factors (2008) (7)
Immunosuppression in IgA nephropathy: how certain are we? (2016) (7)
Mucosal corticosteroid therapy of IgA nephropathy. (2017) (7)
Peripheral chemosensor function is blunted in moderate to severe chronic kidney disease. (2012) (7)
Epidemiology, Pathophysiology, and Therapy of Calciphylaxis (2007) (7)
Association of SGK 1 Gene polymorphisms with type 2 diabetes (2008) (7)
The activated mesangial cell (1992) (7)
Glomerulonephritis triggered by a chronically infected left ventricular assist device (2015) (7)
Uremic Toxins Affecting Cardiovascular Calcification: A Systematic Review (2020) (7)
Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease (2019) (7)
YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy. (2018) (7)
Cardiovascular complications of chronic kidney disease: pioneering studies. (2020) (7)
Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. (2021) (7)
Cisplatin-induced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice (2013) (6)
Cold Shock Proteins Mediate GN with Mesangioproliferation. (2016) (6)
PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy. (2007) (6)
Trends of renal diseases in Germany: review of a regional renal biopsy database from 1990 to 2013 (2019) (6)
Renal elimination of beta-2-microglobulin and myoglobin in patients with normal and impaired renal function. (1990) (6)
Left Ventricular Structure in Patients With Mild-to-Moderate CKD—a Magnetic Resonance Imaging Study (2018) (6)
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure (2022) (6)
Cytokines and inflammation. (2012) (6)
CTLA-4 Polymorphisms in Patients with IgA Nephropathy Correlate with Proteinuria (2018) (6)
Speckle Tracking Echocardiography and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients (2019) (6)
Transplantation: An end to bone disease after renal transplantation? (2013) (6)
Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy (2018) (6)
Pilot study of non‐contrast‐enhanced MRI vs. ultrasound in renal transplant recipients with acquired cystic kidney disease: a prospective intra‐individual comparison (2013) (6)
Time‐dependent lipid profile inversely associates with mortality in hemodialysis patients – independent of inflammation/malnutrition (2021) (5)
Mortality in chronic kidney disease and mineral metabolism. (2011) (5)
Prognostic assessment of IgA nephropathy: how much does histology add? (2016) (5)
Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension. (2019) (5)
Glomerular disease: Efficacy of corticosteroids in high-risk IgA nephropathy (2015) (5)
Is mesangial cell proliferation required for extracellular matrix expansion in glomerular disease? (1994) (5)
Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients. (2000) (5)
Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes (2019) (5)
Adult human kidney organoids originate from CD24+ cells and represent an advanced model for adult polycystic kidney disease (2022) (5)
Time on previous renal replacement therapy is associated with worse outcomes of COVID-19 in a regional cohort of kidney transplant and dialysis patients (2021) (5)
Usefulness of Bioimpedance Spectroscopy for Detection of Hypotensive Episode during Dialysis (2014) (5)
Hyperuricemia and progression of chronic kidney disease: to treat or not to treat? (2021) (5)
Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: the VitaVasK randomized controlled trial (2022) (5)
Cationic dextran induces mesangioproliferative nephritis in rats independent of glomerular IgA deposition. (1997) (4)
Note from the Editorial Office (2008) (4)
Influence of body position, food and beverage consumption on BIS measurements (2010) (4)
CHAPTER 16 – Introduction to Glomerular Disease: Histologic Classification and Pathogenesis (2010) (4)
Extracellular Actin Impairs Glomerular Capillary Repair in Experimental Mesangioproliferative Glomerulonephritis (2003) (4)
Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. (2018) (4)
Bone pain with scintigraphy suggestive of widespread metastases--do not forget phosphate. (2002) (4)
Minimal change nephrotic syndrome in a 74-year-old patient following parenteral administration of sheep cells. (1998) (4)
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression (2021) (4)
Glomerular disease: Rituximab therapy for IgA nephropathy (2017) (4)
Challenging the use of warfarin in patients on dialysis with atrial fibrillation (2015) (4)
Beta 2-microglobulin kinetics during haemofiltration. (1988) (4)
In search of early events in the development of chronic kidney disease: the emerging role for lipocalin-2/NGAL. (2011) (4)
[Early diagnosis of chronic kidney disease. New insights into creatinine and proteinuria]. (2006) (4)
Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury (Journal of Clinical Investigation (2009) 119, (1286-1297) DOI: 10.1172/JCI38399) (2009) (4)
[What is certain in the treatment of glomerulonephritis?] (2018) (4)
Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentarium Just Increase? (2019) (4)
Ten-year advances in immunopathology of glomerulonephritis: translated into patients’ care or lost in translation? (2014) (4)
The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. (2021) (4)
Clinical management of vascular and soft tissue calcifications in chronic kidney disease patients (2010) (3)
Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failure. (2021) (3)
Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation (2020) (3)
Complications Related to Water Treatment, Substitution Fluids and Dialysate Composition (2000) (3)
Clinical aspects of dialysis-related amyloidosis. (1995) (3)
Cre recombinase toxicity in podocytes, a novel genetic model for FSGS in adolescent mice. (2019) (3)
Mineral and bone disorder in chronic kidney disease: pioneering studies. (2020) (3)
A challenge to the kidney community by a man-made crisis. (2022) (3)
A new tool to predict the risk of progression in IgA nephropathy. (2019) (3)
Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. (2021) (3)
Diagnostic aspects of beta 2-microglobulin amyloidosis. (1996) (3)
Next-Generation Morphometry for pathomics-data mining in histopathology (2023) (3)
Speckle-tracking echocardiography in comparison with ejection fraction for prediction of cardiovascular mortality in patients with end-stage renal disease (2021) (3)
Educational Attainment Is Associated With Kidney and Cardiovascular Outcomes in the German CKD (GCKD) Cohort (2022) (3)
Chronic kidney disease: How effective and safe are antiplatelet agents in CKD? (2013) (3)
Current kidney function parameters overestimate kidney tissue repair in reversible experimental kidney disease. (2022) (3)
[Nomenclature for kidney function and kidney diseases - Improving assessment and prognosis through precision and comprehensibility]. (2022) (3)
Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study (2020) (3)
P66 VITAMIN K2 SUPPLEMENTATION REDUCES THE ELEVATED INACTIVE FORM OF THE CALCIFICATION INHIBITOR MATRIX Gla PROTEIN IN HEMODIALYSIS PATIENTS (2010) (3)
Fatal Attraction: Immunoglobulin A and the Glomerular Mesangium. (2019) (3)
Is mycophenolate mofetil an effective treatment for persistent proteinuria in patients with IgA nephropathy? (2006) (3)
Moderator's view: will 'modern' urine proteomics replace 'old-fashioned' renal biopsy? (2015) (3)
[Calciphylaxis. A call for interdisciplinary cooperation]. (2011) (3)
Macrophage activation syndrome in a patient with pulmonary inflammatory myofibroblastic tumour (2012) (3)
Soft tissue calcification in mice is governed by fetuin-A, pyrophosphate and magnesium (2019) (3)
Coumarin use in dialysis patients with arterial fibrillation : yes , after individual risk stratification (2010) (2)
Blood-dialyzer interactions: their role in long-term complications of hemodialysis. (1992) (2)
Glomerular disease: Immunosuppressant-induced reduction of proteinuria in IgAN (2016) (2)
Biochemical basis for transport processes in archinephric duct of the Atlantic hagfish (Myxine glutinosa) (1982) (2)
The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy. (2021) (2)
Принципы ведения гломерулярных болезней (часть 2): итоги согласительной конференции Kidney disease: improving global outcomes (KDIGO) по спорным вопросам (2021) (2)
Identification of central venous hemodialysis catheter-related infection by a semiquantitative culture method. (2007) (2)
GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy (2021) (2)
Editorial report 2010. (2011) (2)
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial (2023) (2)
The longer the better: follow-up in seemingly 'benign' immunoglobulin A nephropathy. (2017) (2)
Experimental pathology - 2 (2009) (2)
A Focus Group Study of Self-Management in Patients With Glomerular Disease (2021) (2)
Quantification of human urinary free secretory component, secretory and nonsecretory IgA by ELISA. (1989) (2)
Diagnostic approaches to AB-amyloidosis. (1991) (2)
Transplantation: basic science and immune-tolerance (2011) (2)
A Core Outcome Set for Trials in Glomerular Disease (2021) (2)
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study (2020) (2)
Models of IgA nephropathy (2010) (2)
Evaluation of Electrocardiographic Parameters Predicting Cardiovascular Events in Patients with End-Stage Renal Disease before and after Transplantation (2019) (2)
Mutant mice provide new insight into the role of (mis-)glycation in IgA nephropathy and other glomerular diseases. (2007) (2)
Fundamentals and applications of immunoadsorption (2010) (2)
Knee-to-knee Bioimpedance Measurements to Monitor Changes in Extracellular Fluid in Haemodynamic-unstable Patients During Dialysis (2019) (2)
CKD pathophysiology and complications (2013) (2)
TO013PROTEINURIA REDUCTION IN IGA NEPHROPATHY BY NEFECON, A TARGETED‑RELEASE FORMULATION OF BUDESONIDE - RESULTS FROM THE NEFIGAN TRIAL (2017) (2)
Heart failure in advanced chronic kidney disease: treatment rationale (2021) (2)
Kidney International and the COVID-19 infection (2020) (2)
[Perspectives 2025 - Positions of the German Society of Internal Medicine]. (2019) (1)
Size heterogeneity of amyloid fibril proteins of beta 2-microglobulin origin in hemodialysis and disease-specific antibodies. (1995) (1)
Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism (2022) (1)
Changes to the Editorial Board and the launch of NDT plus (2007) (1)
Beta 2-microglobulin-derived amyloidosis: clinical use of scintigraphy and insights into its pathogenesis. (1993) (1)
Assessing prognosis in IgA nephropathy. (2022) (1)
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap (2016) (1)
Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients (2022) (1)
Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG). (2023) (1)
Does hemodialysis induce muscular release of myoglobin? (1988) (1)
MP365SUCROFERRIC OXYHYDROXIDE DOES NOT IMPACT THE IPTH-LOWERING EFFECTS OF ORAL VDRAS OR CINACALCET: A POST HOC ANALYSIS OF A PHASE 3 STUDY (2016) (1)
Improving Global Outcomes ( KDIGO ) Controversies Management and treatment of glomerular diseases ( part 1 ) : conclusions from a Kidney Disease : Conference (2019) (1)
TO032CONSEQUENCES AND FATE OF INTRARENAL CRYSTALS IN ADENINE NEPHROPATHY (2016) (1)
Precision medicine in immunoglobulin A nephropathy: still a journey ahead. (2021) (1)
Authors' Reply: Advanced Tertiary Lymphoid Tissues in Protocol Biopsies in Kidney Transplant Recipients: Addressing Additional Methods To Detect Intragraft B Cells. (2022) (1)
International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology. (2023) (1)
The five most cited NDT papers from 2005 to 2009. (2010) (1)
Pro-Angiogenic and Antimesangioproliferative Effects (2012) (1)
AB-Amyloidosis and Monokines (1991) (1)
Atrial fibrillation and chronic kidney disease. (2012) (1)
Reduction of endothelial glycocalyx on peritubular capillaries in chronic kidney disease. (2022) (1)
Mechanisms of Progression in Renal Disease (1999) (1)
Novel insights into osteogenesis and matrix remodelling associated with calci fi c uraemic arteriolopathy (2013) (1)
AB0154 Notch3 is upregulated in lupus nephritis and its deficiency accelerates lupus progression (2018) (1)
IgA nephropathy: a perspective for 2021 (2021) (1)
The management of membranous nephropathy - an update. (2021) (1)
Several β2-Microglobulin Fragments Identified in an Amyloidoma in a Patient with Long-Term Hemodialysis (1991) (1)
FP357 THE CLINICAL EVALUATION OF LOW DOSE HEPARIN IN HEMODIALYSIS: A PROSPECTIVE STUDY USING THE HEPARIN-COATED AN69 ST MEMBRANE (2007) (1)
Epidemiology - cardiovascular outcomes (2013) (1)
No clinically relevant changes in Vitamin D Concentrations with PA21, a Novel Iron-Based Phosphate Binder, Over 52 Weeks (2014) (1)
MO025NON-INVASIVE MOLECULAR IMAGING OF KIDNEY FIBROSIS (2016) (1)
YB-1 IS THE CRUCIAL MEDIATOR OF ANTIFIBROTIC IFN-γ EFFECTS (2005) (1)
SP100KERATINS AS NOVEL MARKERS OF RENAL EPITHELIAL CELL INJURY (2015) (1)
The immunopathogenesis of IgA-nephropathy. (1998) (1)
Effects of Perfusion Pressures on Podocyte Loss in the Isolated Perfused Mouse Kidney. (2021) (1)
MP381CHARACTERISTICS OF RESPONDERS AND NON-RESPONDERS TO TREATMENT WITH SUCROFERRIC OXYHYDROXIDE: A POST HOC ANALYSIS OF A PHASE 3 STUDY (2016) (1)
How I Treat IgA Nephropathy. (2022) (1)
Collagen-specific molecular imaging of renal fibrosis (2020) (1)
[IgA nephropathy: frequent, but rarely diagnosed]. (2003) (1)
Potential Risks of Stem Cell Therapies (2011) (1)
[IgA-nephropathy: the most common type of glomerulonephritis]. (2003) (1)
Cytokines in the progression of renal disease. (1993) (1)
CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC (2011) (1)
Beta-2-microglobulin and dialysis-related amyloidosis. Recent developments. (1989) (1)
Therapy of patients with IgA-nephropathy: a critical appraisal. (2000) (1)
Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation Observational registry. (2021) (1)
SP048UNRAVELING THE MECHANISM OF ACTION OF GLUCOCORTICOIDS IN GLOMERULONEPHRITIS (2015) (1)
Arteriosclerotic aorta calcifications characterized by TEM and electron crystallography (2006) (1)
Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials : A Meta-Analysis of Treatment Effects of Randomized Controlled Trials (2019) (0)
P0794A REAL-WORLD OBSERVATIONAL STUDY OF ETELCALCETIDE USE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN EUROPE (2020) (0)
Differential prognostic utility of adiposity measures in chronic kidney disease. (2023) (0)
Future optimization of hemodialysis procedure by application of electrical impedance spectroscopy (2020) (0)
Diagnosis and Treatment of Patients With FSGS/SRNS: A Delphi Survey (2022) (0)
[Long-term management of dialysis patients. I. Hypertension and anemia]. (1999) (0)
and matrix production in vivo (1997) (0)
MP281CONTRAST-ENHANCED CT IMAGING IN PATIENTS WITH CHRONIC KIDNEY DISEASE (2016) (0)
[Heart & kidney-an unholy alliance]. (2020) (0)
MO056: Alteration of Glycocalyx on Endothelium of Peritubular Capillaries in CKD (2022) (0)
Editorial / Publisher’s Note (2002) (0)
CD8 T cells specific for a glomerular antigen induce renal inflammation in a CD4 help dependent fashion and may cause progressing Glomerulonephritis (2008) (0)
FP349TRENDS OF RENAL DISEASES IN GERMANY: A REVIEW OF A REGIONAL RENAL BIOPSY DATABASE FROM 1990-2013 (2015) (0)
[Magnesium: a kardio-renal viewpoint]. (2016) (0)
TESTING the effects of corticosteroids in patients with IgA nephropathy. (2022) (0)
OUTCOMES OF COVID-2019 IN RENAL TRANSPLANT RECIPIENTS VERSUS CHRONIC HEMODIALYSIS PATIENTS: ANALYSIS OF A REGIONAL COHORT (2020) (0)
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD (2023) (0)
CKD PATHOPHYSIOLOGY AND CLINICAL STUDIES (2014) (0)
Publisher Correction: Non-invasive molecular imaging of kidney diseases (2021) (0)
[Creatinine increase as accidental finding]. (2006) (0)
Comment Nephrology Dialysis Transplantation Cytokines in the progression of renal disease (2005) (0)
[Long-term management of dialysis patients. II. Beta 2-microglobulin associated amyloidosis and acquired cystic kidney disease]. (1999) (0)
SP329VITAMIN K ELIMINATES UREMIC POSTTRANSLATIONAL MODIFICATIONS OF THE GAMMA-GLUTAMYL CARBOXYLASE (2016) (0)
Immunadsorption bei therapierefraktärer Polymyositis (2011) (0)
Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology. (2021) (0)
808-P: Association between Analogue Compared with Human Insulin and the Outcomes of Mortality, Hospitalization, MACE, and Hypoglycemia in Hemodialysis Patients with Type 2 Diabetes: The ARO Research Initiative (2022) (0)
The importance of residual renal function for patients on dialysis (2005) (0)
MO011SNF472 - A POTENTIAL NOVEL CALCIFICATION INHIBITOR IN CKD-MBD (2016) (0)
NON-INVASIVE IN VIVO DETECTION OF AB-AMYLOIDOSIS USING ITS RADIOLABELLED PRECURSOR PROTEIN* (1991) (0)
Survival with low- and high-flux dialysis (2020) (0)
Cardiovascular complications - 2 (2009) (0)
Validation of a Prospective Urinalysis-Based Prediction Model for the Outcome of COVID-19 Disease: A Multicenter Cohort Study (2020) (0)
THE ULTRASTRUCTURE OF ARTERIOSCLEROSIS IN PATIENTS WITH ENDSTAGE RENAL DISEASE (2006) (0)
[Science as a cornerstone of medical education and training]. (2019) (0)
Dialysis / Mineral bone disease 1 (2011) (0)
[Internal Medicine - from Guidelines to "Choosing Wisely"]. (2017) (0)
Acute kidney injury - Human studies (2011) (0)
The authors reply. (2019) (0)
MP173 THE GERMAN CYLCIPHYLAXIS REGISTRY (2013) (0)
Pathophysiology and clinical studies in CKD 5D (2011) (0)
Y-box-binding protein (YB-1) in murine models of hepatic and renal fibrosis (2015) (0)
Poster Session 4: Miscellaneous (2009) (0)
Recommended fluid intake should be tailored to the individual. (2010) (0)
Quantitative brain water content maps. (2015) (0)
Platelet-derived growth factor (PDGF) (2008) (0)
SP096COMMON PATTERNS OF GLOMERULAR EPITHELIAL CELLS IN HUMAN SECONDARY FSGS LESIONS (2015) (0)
Magnesium Improves Cardiac Function in Experimental Uremia by Altering Cardiac Elastin Protein Content (2023) (0)
MO066: The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis (2022) (0)
TO006VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BACKFILTRATION IN THE RENAL GLOMERULUS (2017) (0)
[Incidental finding: elevated serum creatinine]. (2010) (0)
IgA nephropathy - New insights into pathogenesis and therapy (2011) (0)
Cardiovascular disease in patients with chronic kidney disease (2021) (0)
KLKB1 and CLSTN2 are associated with HDL-mediated cholesterol efflux capacity in a genome-wide association study. (2023) (0)
PDGF-D: a novel mediator of mesangioproliferative glomerulonephritis (2004) (0)
Release of heat shock protein 60 is an endogenous enhancer of nephrotoxic nephritis (2003) (0)
Subject Index, Vol. 55, 1990 (1990) (0)
Novel territory for neutrophils in the pathogenesis of ANCA-associated vasculitides ∗ (2009) (0)
Erratum to: Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. (2020) (0)
Vitamin K in vascular health - more than just a role in coagulation (2008) (0)
Change in Albuminuria and GFR Slope as Joint Surrogate Endpoints for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD. (2023) (0)
Heart and bone in CKD - A (2013) (0)
New insights into the pathogenesis of IgA nephropathy (2014) (0)
Testosterone concentrations andoutcomes in hemodialysis patients of the EVOLVE trial. (2022) (0)
FP088HETEROGENEITY AND CLINICAL RELEVANCE OF TERTIARY LYMPHOID TISSUES IN MURINE AND HUMAN KIDNEYS (2018) (0)
Under embargo until June 2 , 2014 , 09 : 30 local time ! LATE BREAKING CLINICAL TRIALS Hyperparathyroidism : Medical or Surgical Treatment ? (2014) (0)
ADVANCED TERTIARY LYMPHOID TISSUES IN PROTOCOL BIOPSIES PREDICT PROGRESSIVE GRAFT DYSFUNCTION IN KIDNEY TRANSPLANT RECIPIENTS (2020) (0)
[Renovascular hypertension--diagnosis and therapy]. (2005) (0)
CKD PROGRESSION MO025 NON-INVASIVE MOLECULAR IMAGING OF KIDNEY FIBROSIS (2016) (0)
SP321DISSECTING THE MOLECULAR DIFFERENCES BETWEEN CHRONIC KIDNEY DISEASE SUBTYPES FROM TRANSCRIPTOMICS DATA (2019) (0)
in Experimental Mesangioproliferative Glomerulonephritis (1998) (0)
Klotho: An Elixir of Youth for the Vasculature? (2011) (0)
Genetic diseases and molecular genetics (2013) (0)
Parathyroid hormone oxidation in chronic kidney disease: clinical relevance? (2021) (0)
MO331LINEAGE TRACING OF REGENERATING PROXIMAL TUBULE CELLS (STC) BY SINGLE CELL PROFILING IN ACUTE KIDNEY INJURY (2021) (0)
DISEASE OF THE MONTH IgA Nephropathy : Recent Developments (2000) (0)
Subject Index Vol. 92, 2002 (2002) (0)
DNA binding protein YB-1 is a part of the neutrophil extracellular trap mediation of kidney damage and cross-organ effects. (2023) (0)
Decoding myofibroblast origins in human kidney fibrosis (2020) (0)
Acknowledgement to the Reviewers (1998) (0)
MP344THE INTERDIALYTIC PERIOD FOR BLOOD COLLECTION INFLUENCES SERUM PHOSPHORUS AND THE RISK OF MORTALITY IN THE COSMOS STUDY (2016) (0)
Salt wars. (2008) (0)
Author Index to Abstracts (2002) (0)
High-fat diet-induced obesity causes an inflammatory microenvironment in the kidneys of aging Long-Evans rats (2019) (0)
In order to improve CKD – MBD outcomes , in 2003 , the National Kidney Foundation launched the Kidney Dialysis (2012) (0)
FC060THE ASSOCIATION BETWEEN FOUR TIMES A WEEK COMPARED TO THREE TIMES A WEEK HAEMODIALYSIS AND SURVIVAL, HOSPITALISATION AND VASCULAR ACCESS COMPLICATIONS IN EUROPEAN IN-CENTRE PATIENTS (2019) (0)
Cell signalling / Growth factors (2011) (0)
Heart-Type Fatty Acid Binding Protein, Cardiovascular Outcomes, and Death: Findings From the German CKD Cohort Study. (2022) (0)
Experimental models of CKD (2013) (0)
CONSTITUTIVE ACTIVATION OF PDGFR-beta IN RENAL MESENCHYMAL CELLS DRIVES RENAL FIBROSIS (2016) (0)
SP600IMPACT OF VASCULAR ACCESS CALCIFICATION ON ARTERIO-VENOUS FISTULA FAILURE: A FIVE-YEAR PROSPECTIVE STUDY (2015) (0)
[Therapy and prophylaxis of renal failure]. (2003) (0)
Results Effects of Selective COX-2 Inhibitors on Mesangiolytic Injury and Albuminuria (2002) (0)
[Strengthen Internal Medicine Generalists]. (2020) (0)
IgA-Nephropathie (2008) (0)
Immunoadsorption in therapy-resistant polymyositis (2011) (0)
Underestimated Risk Indicator of Thromboembolic Events Platelet Hyperaggregability is Highly Prevalent in Patients With Chronic Kidney Disease : An (2013) (0)
GAS6 PROTEIN AND ITS ROLE IN VASCULAR CALCIFICATION (2013) (0)
Impact of the National Institutes of Health Focal Segmental Glomerulosclerosis ( NIH FSGS ) clinical trial on the treatment of steroid-resistant FSGS (2013) (0)
In-Depth Review Management of hyperphosphataemia in chronic kidney disease — challenges and solutions (2013) (0)
New Diagnostic and Therapeutic Aspects in IgA Nephropathy (2008) (0)
Low -turnover (adynamic) bone disease in CKD patients (2010) (0)
How to write and publish a scientific paper (2012) (0)
cell injury Keratins are novel markers of renal epithelial (2016) (0)
Models for acute and chronic kidney diseases (2010) (0)
Ultrasonographic fata morgana. (2003) (0)
Contents Vol. 91, 2002 (2002) (0)
FP631EFFECTS OF SODIUM THIOSULFATE ON CALCIFICATION OF ILIAC ARTERIES IN HEMODIALYSIS PATIENTS- A INTERVENTIONAL DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED STUDY (2019) (0)
FC 079HIGH SERUM PHOSPHATE, A NOVEL POTENTIAL RISK FACTOR FOR BONE FRAGILITY FRACTURES IN THE COSMOS STUDY (2021) (0)
Pathologieklassifikation der Immunglobulin-A-Nephropathie (2011) (0)
Contents Vol. 92, 2002 (2002) (0)
Phosphatbinder@@@Phosphate binders (2017) (0)
[Treatment of IgA nephropathies: a critical viewpoint]. (2000) (0)
Regression of Glomerulosclerosis: Fact or Myth? (2005) (0)
Haplotype analysis of rs9275224, rs2856717, rs9275424, and rs9275596 at the HLA-DQB1/DRB1 locus. (2012) (0)
P1394ASSOCIATION BETWEEN PARATHYROID HORMONE AND MORTALITY IN HAEMODIALYSIS: THE DIABETES MAKES THE DIFFERENCE (2020) (0)
[Retarding progression of chronic kidney disease]. (2023) (0)
Contents Vol. 118, 2011 (2011) (0)
Supplementary Material for: Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients (2016) (0)
[Screening: Let's Seize the Opportunity for Early Detection of Diseases]. (2018) (0)
Collagen expression in renal fibrosis (2021) (0)
MO185: Post-Translational Carbamylation of Sortilin is Associated with Cardiovascular Calcification in Chronic Kidney Disease (2022) (0)
Bacterial and Sterile Inflammation In Vivo YB-1 Is an Early and Central Mediator of (2013) (0)
International Physicians Delphi Survey: Managing Patients With IgA Nephropathy (2022) (0)
[Nephrology 2005/2006. Recent clinical studies and developments in science]. (2006) (0)
CASE REPORT Henoch-Schönlein Purpura Complicated by Cardiac Involvement: Case Report and Review of the Literature (2009) (0)
Bone disease - 2 (2009) (0)
[Nephrology -- familiar knowledge in the light of new discoveries in molecular and cell biology]. (2005) (0)
Author Index/Subject Index Proceedings (2002) (0)
Intestinal permeability in patients with IgA nephropathy and other glomerular diseases: an observational study (2022) (0)
Molecular Biology/Cell Biology/Human Genetics/Anatomy/ Embryology (2008) (0)
Looking back and moving forward. (2017) (0)
[Readers' letters concerning F, Keller et al: "Financial incentives and dialysis"]. (2008) (0)
MO326CORTICOSTEROIDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REPORTED ADVERSE EVENTS IN RANDOMISED CONTROLLED TRIALS (2021) (0)
Highlights of the 2015 ERA-EDTA Congress--glomerular diseases. (2016) (0)
SP277CONSTITUTIVE ACTIVATION OF PDGFR-β IN RENAL MESENCHYMAL CELLS DRIVES RENAL FIBROSIS (2016) (0)
A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats. (2021) (0)
Imaging of dialysis-related amyloid (AB-amyloid) deposits with radiolabelled microglobulin (2001) (0)
Opponent's comments. (2016) (0)
Management and treatment of glomerular diseases ( part 2 ) : conclusions from a Kidney Disease : Conference (2019) (0)
Author Correction: Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits (2023) (0)
Contents Vol. 93, 2003 (2003) (0)
Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey (2022) (0)
The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis (2022) (0)
Ten-year advances in immunopathology of glomerulonephritis: translated into patients’ care or lost in translation? (2014) (0)
MP092EXPRESSION OF KERATIN 17 IN RENAL INJURY INDICATES TUBULAR STRESS AND DEDIFFERENTIATION (2016) (0)
Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis (2019) (0)
Quantitative Angiography as a Diagnostic Tool for Objective Control of Rheopheretic Treatment in Age Related Macular Degeneration (AMD) (2006) (0)
Comparative analysis of C5aR and C5L2 receptor deficiency in liver and kidney fibrosis (2015) (0)
PowerPoint Slides for: Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients (2016) (0)
Heterogeneity and clinical relevance of tertiary lymphoid tissues in murine and human kidney (2018) (0)
Bone and mineral diseases - 1 (2012) (0)
Subject Index Vol. 91, 2002 (2002) (0)
Contrast-enhanced CT imaging in patients with chronic kidney disease (2016) (0)
Contents, Vol. 55, 1990 (1990) (0)
MO442ACUTE ADVERSE EFFECTS OF LOW POTASSIUM ON HEART AND KIDNEY* (2021) (0)
Central blood pressure: nice to know but not yet ready for routine practice. (2023) (0)
Macrophage Migration Inhibitory Factor Limits Renal In fl ammation and Fibrosis by Counteracting Tubular Cell Cycle Arrest (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jürgen Floege?

Jürgen Floege is affiliated with the following schools:

Jürgen Floege's Academic­Influence.com Rankings

Why Is Jürgen Floege Influential?

Jürgen Floege's Published Works

Published Works

What Schools Are Affiliated With Jürgen Floege?

Jürgen Floege's AcademicInfluence.com Rankings